Home > Our Services > Cancer (Oncology) > Clinical Trials - Physician Information

 

Clinical Trials

The St.Vincent Center for Cancer Care is committed to bringing comprehensive, cutting edge cancer care through a multi-disciplinary approach including access to a variety of clinical trials. As a participant in the NCI Community Cancer Center Program (NCCCP) Pilot, St.Vincent is committed to offering residents of Indiana and beyond access to research-based cancer care. By expanding clinical trials and cancer care we hope to make it easier to recieve high-quality cancer screening, prevention, treatment, and palliative care services. Please see a list of our clinical trials for more information.


 

Search for Clinical Trials at the Center for Cancer Care

Use the following search options to find clinical trials taking place. Contact the Data Analyst listed on the trial for additional information. Our database lists only trials that are currently open for enrollment. Please check back as new clinical trials are added on an ongoing basis.

 

 

Breast

Protocol # NSABP 43
Protocol Title A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Data Analyst

Claudia Lord, cplord@stvincent.org

 

 

Protocol # CALGB 40503
Protocol Title Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) For Women with Hormone Receptor-Positive Advanced Breast Cancer
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # ECOG 1105
Protocol Title A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # IBCSG 24-02
Protocol Title Suppression of Ovarian Function Trial (SOFT) A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer Tamoxifen versus Ovarian function suppression + tamoxifen versus Ovarian function suppression + exemestane
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # NSABP B39
Protocol Title A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # NSABP B40
Protocol Title A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # NSABP B41
Protocol Title A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # NSABP B42
Protocol Title A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # NSABP PACCT-1
Protocol Title <Trial Assigning Individualized Options for Treatment: The TAILORx Trial: Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # NSABP/ECOG ALTTO
Protocol Title Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Data Analyst Masheka Fuqua; mrfugua@stvincent.org
Protocol # SWOG S0226
Protocol Title Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # SWOG S0307
Protocol Title Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # SWOG S0500
Protocol Title A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Back to top

 

 

Colo-Rectal

Protocol # RTOG 0822
Protocol Title A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT) IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # CALGB/SWOG C80405 (on hold)
Protocol Title A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # CALGB/SWOG C80405 (on hold)
Protocol Title A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Data Analyst Claudia Lord; cplord@stvincent.org

Back to top

 

 

Esophageal

Protocol # RTOG 0436
Protocol Title A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery
Data Analyst Claudia Lord; cplord@stvincent.org

Back to top

 

 

Hematology

No Hematology trials at this time.

Back to top

 

 

Head and Neck

Protocol # RTOG 0522
Protocol Title A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Protocol # RTOG 0514
Protocol Title ESTABLISHMENT OF A HEAD AND NECK CANCER TISSUE/SPECIMEN BANK
Data Analyst Claudia Lord; cplord@stvincent.org

Back to top

 

 

Lung

Protocol # CALGB 30610
Protocol Title Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Data Analyst MashekaFuqua; mrfugua@stvincent.org

Protocol # RTOG 0617
Protocol Title A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444) IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER
Data Analyst Claudia Lord; cplord@stvincent.org

Protocol # ECOG 1505
Protocol Title A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Data Analyst Masheka Fuqua; mrfugua@stvincent.org

Back to top

 

 

Other

Disease Site Other 
Protocol # GOG 0248
Protocol Title A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864, IND # 61010) or the Combination of Hormonal Therapy plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma
Data Analyst Shirley Morrison, samorri1@stvincent.org

 

 

Disease Site Other
Protocol # GOG-0129Q 
Protocol Title Phase II Evaluation of Gemcitabine (Gemzar, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma (Eli Lilly Study B9E-US-X472
Data Analyst Shirley Morrison; samorri1@stvincent.org

 

 

Disease Site Other
Protocol # Precision
Protocol Title ChemoFx® Observational Study: A non-interventional, longitudinal, multi-center initiative examining outcomes associated with the use of the ChemoFx Assay® in solid tumor malignancies
Data Analyst Shirley Morrison; samorri1@stvincent.org

 

Disease Site Gyn
Protocol # EC-FV-04
Protocol Title A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination, versus PLD Alone, in Subjects with Platinum-Resistant Ovarian Cancer
Data Analyst

Shirley Morrison, samorri1@stvincent.org


Disease Site Gyn
Protocol # RTOG 0417
Protocol Title A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma
Data Analyst

Shirley Morrison, samorri1@stvincent.org

 

Disease Site Gyn
Protocol # Ortho Biotech
Protocol Title Phase II Single Arm Study of Carboplatin & Doxil plus Bevcizumab in Subjects with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # HOG GYN06-111
Protocol Title A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrant Ovarian Cancer or Primary Peritoneal Carcinomatosis
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0235
Protocol Title A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # Morphotek
Protocol Title

 

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with First Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0209
Protocol Title Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0210
Protocol Title A molecular Staging Study of Endometrial Carcinoma
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0212
Protocol Title A randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Pacitaxel, or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0213
Protocol Title A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #7921)
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0214
Protocol Title Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND#79,610)
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Other
Protocol # GOG 0215
Protocol Title A Phase Ii Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Minderal Density of the Lumbar Spine in Women Who Elect to Undergo Surgery that Results in Removal of Both Ovaries
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0218
Protocol Title A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND #7921) followed by Placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal Cancer NCI-Supplied Agent(s): Bevacizumab/Placebo (NSC #704856, IND #7921)
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # GOG 0232C
Protocol Title A Phase II Evaluation of Pacitaxel (Taxol®, NSC#673089), Carboplatin (Paraplatin®, NSC#241240), and BSI-201 (NSC#746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # Ohio State University
Protocol Title A Phase II Study of Gemcitabine/Carbonplatin/Bevacizumab(Avastin®) in Platinum-sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # Precision
Protocol Title Chemoresponse Assay Validation Trial: A Non-interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay with Progression-free Survival in Patients with Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Data Analyst Shirley Morrison; samorri1@stvincent.org

Disease Site Gyn
Protocol # Onconova
Protocol Title Phase II Single-Arm Study of ON 01910.Na By 2-Hour Infusion in Patients With Recurring Platinum-Resistant Ovarian Cancer
Data Analyst Shirley Morrison; samorri1@stvincent.org

 

 

Disease Site
Protocol # GOG 0240
Protocol Title A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Data Analyst

Shirley Morrison; samorri1@stvincent.org

 

Disease Site

 Brain
Protocol #  
Protocol Title A Feasibility Trial of Concurrent Radiation, Temozolomide and Bevacizumab Followed by Temozolomide and Bevacizumab for Resectable and Unresectable Glioblastoma Multiforme of the Brain
Data Analyst Claudia Lord; cplord@stvincent.org

Back to top


Send Us A Message  |  Sitemap Copyright Policy |  Website Privacy Policy  |  Terms of Service
Copyright © 2006 St.Vincent Health